Global Prostate Cancer-targeted PET Imaging Agent Market Growth 2026-2032
The global Prostate Cancer-targeted PET Imaging Agent market size is predicted to grow from US$ 1480 million in 2025 to US$ 2446 million in 2032; it is expected to grow at a CAGR of 7.3% from 2026 to 2032.
In 2025, the global production of prostate cancer-targeted PET imaging agents reached 2.8812 million units, with an average selling price of 525 USD per unit. The global annual production capacity for prostate cancer-targeted PET imaging agents is approximately 5 million units, with a gross margin of about 30.4%. A prostate cancer-targeted PET imaging agent is a radiopharmaceutical administered intravenously. Its mechanism involves the use of specific molecular probes (such as PSMA?targeting agents, FAPI, etc.) that bind to specific targets on the surface of prostate cancer cells or in the tumor microenvironment, after which the radioactive signals are captured by a PET scanner to generate whole?body three?dimensional images. These imaging agents can detect primary lesions, micrometastases, and recurrent lesions of prostate cancer with high sensitivity and specificity, and their imaging accuracy is significantly superior to that of conventional CT or bone scans. They are playing an increasingly important role in initial staging, biochemical recurrence localization, and treatment response assessment for prostate cancer. Depending on the targeting targets, the most commonly used in clinical practice are PSMA?targeted imaging agents, while novel agents such as FAPI show complementary value in prostate cancers that are PSMA?negative or have low PSMA expression. The upstream of prostate cancer-targeted PET imaging agents includes radionuclides (such as gallium?68, fluorine?18, etc.), PSMA?targeting ligands (small molecules/peptides/antibodies), and nanocarriers/chelators. The midstream consists of manufacturers of prostate cancer-targeted PET imaging agents, and the downstream is mainly used in nuclear medicine and molecular imaging, precision tumor diagnostics, and radiopharmaceuticals and nuclear pharmacy.
Currently, the market for prostate cancer-targeted PET imaging agents is in a phase of rapid evolution and accelerating clinical adoption, with its strategic value in the full-course management of prostate cancer being widely recognized. With the diversified development of molecular probe technologies, PSMA-targeted agents have taken a leading position, while novel targeted agents such as FAPI have effectively addressed the clinical needs of patients with PSMA-negative or low-PSMA-expression tumors, forming a multi-target complementary application landscape. At the clinical practice level, the application scope of these imaging agents continues to expand, extending from traditional detection of advanced metastases to critical areas such as initial staging, precise localization of biochemical recurrence, treatment strategy guidance, and dynamic therapy monitoring, thereby serving as a key driver for precision nuclear medicine. On the technical front, continuous improvements in radionuclide conjugation processes, automated synthesis modules, and rapid distribution systems have significantly enhanced the availability and clinical convenience of these agents. However, challenges inherent to radiopharmaceuticals, such as short half-lives, stringent regulatory approval procedures, and the training of interdisciplinary professionals, remain common bottlenecks for the industry. Overall, the market ecosystem is maturing, clinical demand is steadily growing, and competition is gradually shifting from single-product offerings to comprehensive capabilities encompassing R&D, service responsiveness, and clinical collaboration. Future directions increasingly emphasize individualized dosing regimens, novel target development, and deep integration of theranostics, presenting an overall trend of precision, diversity, and synergy.
Report Scope
LP Information, Inc. (LPI) ' newest research report, the “Prostate Cancer-targeted PET Imaging Agent Industry Forecast” looks at past sales and reviews total world Prostate Cancer-targeted PET Imaging Agent sales in 2025, providing a comprehensive analysis by region and market sector of projected Prostate Cancer-targeted PET Imaging Agent sales for 2026 through 2032. With Prostate Cancer-targeted PET Imaging Agent sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prostate Cancer-targeted PET Imaging Agent industry.
This Insight Report provides a comprehensive analysis of the global Prostate Cancer-targeted PET Imaging Agent landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Prostate Cancer-targeted PET Imaging Agent portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Prostate Cancer-targeted PET Imaging Agent market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prostate Cancer-targeted PET Imaging Agent and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prostate Cancer-targeted PET Imaging Agent.
This report presents a comprehensive overview, market shares, and growth opportunities of Prostate Cancer-targeted PET Imaging Agent market by product type, application, key manufacturers and key regions and countries.
In 2025, the global production of prostate cancer-targeted PET imaging agents reached 2.8812 million units, with an average selling price of 525 USD per unit. The global annual production capacity for prostate cancer-targeted PET imaging agents is approximately 5 million units, with a gross margin of about 30.4%. A prostate cancer-targeted PET imaging agent is a radiopharmaceutical administered intravenously. Its mechanism involves the use of specific molecular probes (such as PSMA?targeting agents, FAPI, etc.) that bind to specific targets on the surface of prostate cancer cells or in the tumor microenvironment, after which the radioactive signals are captured by a PET scanner to generate whole?body three?dimensional images. These imaging agents can detect primary lesions, micrometastases, and recurrent lesions of prostate cancer with high sensitivity and specificity, and their imaging accuracy is significantly superior to that of conventional CT or bone scans. They are playing an increasingly important role in initial staging, biochemical recurrence localization, and treatment response assessment for prostate cancer. Depending on the targeting targets, the most commonly used in clinical practice are PSMA?targeted imaging agents, while novel agents such as FAPI show complementary value in prostate cancers that are PSMA?negative or have low PSMA expression. The upstream of prostate cancer-targeted PET imaging agents includes radionuclides (such as gallium?68, fluorine?18, etc.), PSMA?targeting ligands (small molecules/peptides/antibodies), and nanocarriers/chelators. The midstream consists of manufacturers of prostate cancer-targeted PET imaging agents, and the downstream is mainly used in nuclear medicine and molecular imaging, precision tumor diagnostics, and radiopharmaceuticals and nuclear pharmacy.
Currently, the market for prostate cancer-targeted PET imaging agents is in a phase of rapid evolution and accelerating clinical adoption, with its strategic value in the full-course management of prostate cancer being widely recognized. With the diversified development of molecular probe technologies, PSMA-targeted agents have taken a leading position, while novel targeted agents such as FAPI have effectively addressed the clinical needs of patients with PSMA-negative or low-PSMA-expression tumors, forming a multi-target complementary application landscape. At the clinical practice level, the application scope of these imaging agents continues to expand, extending from traditional detection of advanced metastases to critical areas such as initial staging, precise localization of biochemical recurrence, treatment strategy guidance, and dynamic therapy monitoring, thereby serving as a key driver for precision nuclear medicine. On the technical front, continuous improvements in radionuclide conjugation processes, automated synthesis modules, and rapid distribution systems have significantly enhanced the availability and clinical convenience of these agents. However, challenges inherent to radiopharmaceuticals, such as short half-lives, stringent regulatory approval procedures, and the training of interdisciplinary professionals, remain common bottlenecks for the industry. Overall, the market ecosystem is maturing, clinical demand is steadily growing, and competition is gradually shifting from single-product offerings to comprehensive capabilities encompassing R&D, service responsiveness, and clinical collaboration. Future directions increasingly emphasize individualized dosing regimens, novel target development, and deep integration of theranostics, presenting an overall trend of precision, diversity, and synergy.
Report Scope
LP Information, Inc. (LPI) ' newest research report, the “Prostate Cancer-targeted PET Imaging Agent Industry Forecast” looks at past sales and reviews total world Prostate Cancer-targeted PET Imaging Agent sales in 2025, providing a comprehensive analysis by region and market sector of projected Prostate Cancer-targeted PET Imaging Agent sales for 2026 through 2032. With Prostate Cancer-targeted PET Imaging Agent sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prostate Cancer-targeted PET Imaging Agent industry.
This Insight Report provides a comprehensive analysis of the global Prostate Cancer-targeted PET Imaging Agent landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Prostate Cancer-targeted PET Imaging Agent portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Prostate Cancer-targeted PET Imaging Agent market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prostate Cancer-targeted PET Imaging Agent and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prostate Cancer-targeted PET Imaging Agent.
This report presents a comprehensive overview, market shares, and growth opportunities of Prostate Cancer-targeted PET Imaging Agent market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- 68Ga
- 18F
Segmentation by Core Carrier Materials:
- First Generation
- Second Generation
Segmentation by Mechanism of Action:
- Active Targeting
- Passive Targeting
Segmentation by Application:
- Nuclear Medicine and Molecular Imaging
- Precision Oncology Diagnostics
- Radiopharmaceuticals and Radiopharmaceuticals
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Lantheus
- Telix Pharmaceuticals
- Novartis
- Blue Earth Diagnostics?Bracco?
- Sinotau
- DC PHARMA
- Clarity Pharmaceuticals
- Hengrui Pharma
- CRAND PHARMACEUTICAL
- Norroy Bioscience
- HUAYI RADIOPHARMACEUTICALS
- Yunhe Pharma
- C Ray Therapeutics
- Curium Holding France S.A.S.
- ABX advanced biochemical compounds GmbH
- Isotopia Molecular Imaging Ltd.
Key Questions Addressed in this Report
- What is the 10-year outlook for the global Prostate Cancer-targeted PET Imaging Agent market?
- What factors are driving Prostate Cancer-targeted PET Imaging Agent market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Prostate Cancer-targeted PET Imaging Agent market opportunities vary by end market size?
- How does Prostate Cancer-targeted PET Imaging Agent break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Prostate Cancer-targeted PET Imaging Agent Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Prostate Cancer-targeted PET Imaging Agent by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Prostate Cancer-targeted PET Imaging Agent by Country/Region, 2021, 2025 & 2032
2.2 Prostate Cancer-targeted PET Imaging Agent Segment by Type
2.2.1 68Ga
2.2.2 18F
2.2.3 Prostate Cancer-targeted PET Imaging Agent Sales by Type
2.2.3.1 Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Type (2021-2026)
2.2.3.2 Global Prostate Cancer-targeted PET Imaging Agent Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Type (2021-2026)
2.3 Prostate Cancer-targeted PET Imaging Agent Segment by Core Carrier Materials
2.3.1 First Generation
2.3.2 Second Generation
2.3.3 Prostate Cancer-targeted PET Imaging Agent Sales by Core Carrier Materials
2.3.3.1 Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Core Carrier Materials (2021-2026)
2.3.3.2 Global Prostate Cancer-targeted PET Imaging Agent Revenue and Market Share by Core Carrier Materials (2021-2026)
2.3.3.3 Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Core Carrier Materials (2021-2026)
2.4 Prostate Cancer-targeted PET Imaging Agent Segment by Mechanism of Action
2.4.1 Active Targeting
2.4.2 Passive Targeting
2.4.3 Prostate Cancer-targeted PET Imaging Agent Sales by Mechanism of Action
2.4.3.1 Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Mechanism of Action (2021-2026)
2.4.3.2 Global Prostate Cancer-targeted PET Imaging Agent Revenue and Market Share by Mechanism of Action (2021-2026)
2.4.3.3 Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Mechanism of Action (2021-2026)
2.5 Prostate Cancer-targeted PET Imaging Agent Segment by Application
2.5.1 Nuclear Medicine and Molecular Imaging
2.5.2 Precision Oncology Diagnostics
2.5.3 Radiopharmaceuticals and Radiopharmaceuticals
2.5.4 Prostate Cancer-targeted PET Imaging Agent Sales by Application
2.5.4.1 Global Prostate Cancer-targeted PET Imaging Agent Sale Market Share by Application (2021-2026)
2.5.4.2 Global Prostate Cancer-targeted PET Imaging Agent Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Prostate Cancer-targeted PET Imaging Agent Breakdown Data by Company
3.1.1 Global Prostate Cancer-targeted PET Imaging Agent Annual Sales by Company (2021-2026)
3.1.2 Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Company (2021-2026)
3.2 Global Prostate Cancer-targeted PET Imaging Agent Annual Revenue by Company (2021-2026)
3.2.1 Global Prostate Cancer-targeted PET Imaging Agent Revenue by Company (2021-2026)
3.2.2 Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Company (2021-2026)
3.3 Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Company
3.4 Key Manufacturers Prostate Cancer-targeted PET Imaging Agent Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Prostate Cancer-targeted PET Imaging Agent Product Location Distribution
3.4.2 Players Prostate Cancer-targeted PET Imaging Agent Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PROSTATE CANCER-TARGETED PET IMAGING AGENT BY GEOGRAPHIC REGION
4.1 World Historic Prostate Cancer-targeted PET Imaging Agent Market Size by Geographic Region (2021-2026)
4.1.1 Global Prostate Cancer-targeted PET Imaging Agent Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Prostate Cancer-targeted PET Imaging Agent Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Prostate Cancer-targeted PET Imaging Agent Market Size by Country/Region (2021-2026)
4.2.1 Global Prostate Cancer-targeted PET Imaging Agent Annual Sales by Country/Region (2021-2026)
4.2.2 Global Prostate Cancer-targeted PET Imaging Agent Annual Revenue by Country/Region (2021-2026)
4.3 Americas Prostate Cancer-targeted PET Imaging Agent Sales Growth
4.4 APAC Prostate Cancer-targeted PET Imaging Agent Sales Growth
4.5 Europe Prostate Cancer-targeted PET Imaging Agent Sales Growth
4.6 Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales Growth
5 AMERICAS
5.1 Americas Prostate Cancer-targeted PET Imaging Agent Sales by Country
5.1.1 Americas Prostate Cancer-targeted PET Imaging Agent Sales by Country (2021-2026)
5.1.2 Americas Prostate Cancer-targeted PET Imaging Agent Revenue by Country (2021-2026)
5.2 Americas Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026)
5.3 Americas Prostate Cancer-targeted PET Imaging Agent Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Prostate Cancer-targeted PET Imaging Agent Sales by Region
6.1.1 APAC Prostate Cancer-targeted PET Imaging Agent Sales by Region (2021-2026)
6.1.2 APAC Prostate Cancer-targeted PET Imaging Agent Revenue by Region (2021-2026)
6.2 APAC Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026)
6.3 APAC Prostate Cancer-targeted PET Imaging Agent Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Prostate Cancer-targeted PET Imaging Agent by Country
7.1.1 Europe Prostate Cancer-targeted PET Imaging Agent Sales by Country (2021-2026)
7.1.2 Europe Prostate Cancer-targeted PET Imaging Agent Revenue by Country (2021-2026)
7.2 Europe Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026)
7.3 Europe Prostate Cancer-targeted PET Imaging Agent Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Prostate Cancer-targeted PET Imaging Agent by Country
8.1.1 Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales by Country (2021-2026)
8.1.2 Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Revenue by Country (2021-2026)
8.2 Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026)
8.3 Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Prostate Cancer-targeted PET Imaging Agent
10.3 Manufacturing Process Analysis of Prostate Cancer-targeted PET Imaging Agent
10.4 Industry Chain Structure of Prostate Cancer-targeted PET Imaging Agent
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Prostate Cancer-targeted PET Imaging Agent Distributors
11.3 Prostate Cancer-targeted PET Imaging Agent Customer
12 WORLD FORECAST REVIEW FOR PROSTATE CANCER-TARGETED PET IMAGING AGENT BY GEOGRAPHIC REGION
12.1 Global Prostate Cancer-targeted PET Imaging Agent Market Size Forecast by Region
12.1.1 Global Prostate Cancer-targeted PET Imaging Agent Forecast by Region (2027-2032)
12.1.2 Global Prostate Cancer-targeted PET Imaging Agent Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Prostate Cancer-targeted PET Imaging Agent Forecast by Type (2027-2032)
12.7 Global Prostate Cancer-targeted PET Imaging Agent Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Lantheus
13.1.1 Lantheus Company Information
13.1.2 Lantheus Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.1.3 Lantheus Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Lantheus Main Business Overview
13.1.5 Lantheus Latest Developments
13.2 Telix Pharmaceuticals
13.2.1 Telix Pharmaceuticals Company Information
13.2.2 Telix Pharmaceuticals Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.2.3 Telix Pharmaceuticals Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Telix Pharmaceuticals Main Business Overview
13.2.5 Telix Pharmaceuticals Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.3.3 Novartis Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 Blue Earth Diagnostics?Bracco?
13.4.1 Blue Earth Diagnostics?Bracco? Company Information
13.4.2 Blue Earth Diagnostics?Bracco? Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.4.3 Blue Earth Diagnostics?Bracco? Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Blue Earth Diagnostics?Bracco? Main Business Overview
13.4.5 Blue Earth Diagnostics?Bracco? Latest Developments
13.5 Sinotau
13.5.1 Sinotau Company Information
13.5.2 Sinotau Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.5.3 Sinotau Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sinotau Main Business Overview
13.5.5 Sinotau Latest Developments
13.6 DC PHARMA
13.6.1 DC PHARMA Company Information
13.6.2 DC PHARMA Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.6.3 DC PHARMA Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 DC PHARMA Main Business Overview
13.6.5 DC PHARMA Latest Developments
13.7 Clarity Pharmaceuticals
13.7.1 Clarity Pharmaceuticals Company Information
13.7.2 Clarity Pharmaceuticals Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.7.3 Clarity Pharmaceuticals Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Clarity Pharmaceuticals Main Business Overview
13.7.5 Clarity Pharmaceuticals Latest Developments
13.8 Hengrui Pharma
13.8.1 Hengrui Pharma Company Information
13.8.2 Hengrui Pharma Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.8.3 Hengrui Pharma Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Hengrui Pharma Main Business Overview
13.8.5 Hengrui Pharma Latest Developments
13.9 CRAND PHARMACEUTICAL
13.9.1 CRAND PHARMACEUTICAL Company Information
13.9.2 CRAND PHARMACEUTICAL Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.9.3 CRAND PHARMACEUTICAL Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 CRAND PHARMACEUTICAL Main Business Overview
13.9.5 CRAND PHARMACEUTICAL Latest Developments
13.10 Norroy Bioscience
13.10.1 Norroy Bioscience Company Information
13.10.2 Norroy Bioscience Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.10.3 Norroy Bioscience Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Norroy Bioscience Main Business Overview
13.10.5 Norroy Bioscience Latest Developments
13.11 HUAYI RADIOPHARMACEUTICALS
13.11.1 HUAYI RADIOPHARMACEUTICALS Company Information
13.11.2 HUAYI RADIOPHARMACEUTICALS Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.11.3 HUAYI RADIOPHARMACEUTICALS Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 HUAYI RADIOPHARMACEUTICALS Main Business Overview
13.11.5 HUAYI RADIOPHARMACEUTICALS Latest Developments
13.12 Yunhe Pharma
13.12.1 Yunhe Pharma Company Information
13.12.2 Yunhe Pharma Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.12.3 Yunhe Pharma Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Yunhe Pharma Main Business Overview
13.12.5 Yunhe Pharma Latest Developments
13.13 C Ray Therapeutics
13.13.1 C Ray Therapeutics Company Information
13.13.2 C Ray Therapeutics Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.13.3 C Ray Therapeutics Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 C Ray Therapeutics Main Business Overview
13.13.5 C Ray Therapeutics Latest Developments
13.14 Curium Holding France S.A.S.
13.14.1 Curium Holding France S.A.S. Company Information
13.14.2 Curium Holding France S.A.S. Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.14.3 Curium Holding France S.A.S. Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Curium Holding France S.A.S. Main Business Overview
13.14.5 Curium Holding France S.A.S. Latest Developments
13.15 ABX advanced biochemical compounds GmbH
13.15.1 ABX advanced biochemical compounds GmbH Company Information
13.15.2 ABX advanced biochemical compounds GmbH Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.15.3 ABX advanced biochemical compounds GmbH Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 ABX advanced biochemical compounds GmbH Main Business Overview
13.15.5 ABX advanced biochemical compounds GmbH Latest Developments
13.16 Isotopia Molecular Imaging Ltd.
13.16.1 Isotopia Molecular Imaging Ltd. Company Information
13.16.2 Isotopia Molecular Imaging Ltd. Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.16.3 Isotopia Molecular Imaging Ltd. Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Isotopia Molecular Imaging Ltd. Main Business Overview
13.16.5 Isotopia Molecular Imaging Ltd. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Prostate Cancer-targeted PET Imaging Agent Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Prostate Cancer-targeted PET Imaging Agent by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Prostate Cancer-targeted PET Imaging Agent by Country/Region, 2021, 2025 & 2032
2.2 Prostate Cancer-targeted PET Imaging Agent Segment by Type
2.2.1 68Ga
2.2.2 18F
2.2.3 Prostate Cancer-targeted PET Imaging Agent Sales by Type
2.2.3.1 Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Type (2021-2026)
2.2.3.2 Global Prostate Cancer-targeted PET Imaging Agent Revenue and Market Share by Type (2021-2026)
2.2.3.3 Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Type (2021-2026)
2.3 Prostate Cancer-targeted PET Imaging Agent Segment by Core Carrier Materials
2.3.1 First Generation
2.3.2 Second Generation
2.3.3 Prostate Cancer-targeted PET Imaging Agent Sales by Core Carrier Materials
2.3.3.1 Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Core Carrier Materials (2021-2026)
2.3.3.2 Global Prostate Cancer-targeted PET Imaging Agent Revenue and Market Share by Core Carrier Materials (2021-2026)
2.3.3.3 Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Core Carrier Materials (2021-2026)
2.4 Prostate Cancer-targeted PET Imaging Agent Segment by Mechanism of Action
2.4.1 Active Targeting
2.4.2 Passive Targeting
2.4.3 Prostate Cancer-targeted PET Imaging Agent Sales by Mechanism of Action
2.4.3.1 Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Mechanism of Action (2021-2026)
2.4.3.2 Global Prostate Cancer-targeted PET Imaging Agent Revenue and Market Share by Mechanism of Action (2021-2026)
2.4.3.3 Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Mechanism of Action (2021-2026)
2.5 Prostate Cancer-targeted PET Imaging Agent Segment by Application
2.5.1 Nuclear Medicine and Molecular Imaging
2.5.2 Precision Oncology Diagnostics
2.5.3 Radiopharmaceuticals and Radiopharmaceuticals
2.5.4 Prostate Cancer-targeted PET Imaging Agent Sales by Application
2.5.4.1 Global Prostate Cancer-targeted PET Imaging Agent Sale Market Share by Application (2021-2026)
2.5.4.2 Global Prostate Cancer-targeted PET Imaging Agent Revenue and Market Share by Application (2021-2026)
2.5.4.3 Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Prostate Cancer-targeted PET Imaging Agent Breakdown Data by Company
3.1.1 Global Prostate Cancer-targeted PET Imaging Agent Annual Sales by Company (2021-2026)
3.1.2 Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Company (2021-2026)
3.2 Global Prostate Cancer-targeted PET Imaging Agent Annual Revenue by Company (2021-2026)
3.2.1 Global Prostate Cancer-targeted PET Imaging Agent Revenue by Company (2021-2026)
3.2.2 Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Company (2021-2026)
3.3 Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Company
3.4 Key Manufacturers Prostate Cancer-targeted PET Imaging Agent Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Prostate Cancer-targeted PET Imaging Agent Product Location Distribution
3.4.2 Players Prostate Cancer-targeted PET Imaging Agent Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR PROSTATE CANCER-TARGETED PET IMAGING AGENT BY GEOGRAPHIC REGION
4.1 World Historic Prostate Cancer-targeted PET Imaging Agent Market Size by Geographic Region (2021-2026)
4.1.1 Global Prostate Cancer-targeted PET Imaging Agent Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Prostate Cancer-targeted PET Imaging Agent Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Prostate Cancer-targeted PET Imaging Agent Market Size by Country/Region (2021-2026)
4.2.1 Global Prostate Cancer-targeted PET Imaging Agent Annual Sales by Country/Region (2021-2026)
4.2.2 Global Prostate Cancer-targeted PET Imaging Agent Annual Revenue by Country/Region (2021-2026)
4.3 Americas Prostate Cancer-targeted PET Imaging Agent Sales Growth
4.4 APAC Prostate Cancer-targeted PET Imaging Agent Sales Growth
4.5 Europe Prostate Cancer-targeted PET Imaging Agent Sales Growth
4.6 Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales Growth
5 AMERICAS
5.1 Americas Prostate Cancer-targeted PET Imaging Agent Sales by Country
5.1.1 Americas Prostate Cancer-targeted PET Imaging Agent Sales by Country (2021-2026)
5.1.2 Americas Prostate Cancer-targeted PET Imaging Agent Revenue by Country (2021-2026)
5.2 Americas Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026)
5.3 Americas Prostate Cancer-targeted PET Imaging Agent Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Prostate Cancer-targeted PET Imaging Agent Sales by Region
6.1.1 APAC Prostate Cancer-targeted PET Imaging Agent Sales by Region (2021-2026)
6.1.2 APAC Prostate Cancer-targeted PET Imaging Agent Revenue by Region (2021-2026)
6.2 APAC Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026)
6.3 APAC Prostate Cancer-targeted PET Imaging Agent Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Prostate Cancer-targeted PET Imaging Agent by Country
7.1.1 Europe Prostate Cancer-targeted PET Imaging Agent Sales by Country (2021-2026)
7.1.2 Europe Prostate Cancer-targeted PET Imaging Agent Revenue by Country (2021-2026)
7.2 Europe Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026)
7.3 Europe Prostate Cancer-targeted PET Imaging Agent Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Prostate Cancer-targeted PET Imaging Agent by Country
8.1.1 Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales by Country (2021-2026)
8.1.2 Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Revenue by Country (2021-2026)
8.2 Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026)
8.3 Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Prostate Cancer-targeted PET Imaging Agent
10.3 Manufacturing Process Analysis of Prostate Cancer-targeted PET Imaging Agent
10.4 Industry Chain Structure of Prostate Cancer-targeted PET Imaging Agent
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Prostate Cancer-targeted PET Imaging Agent Distributors
11.3 Prostate Cancer-targeted PET Imaging Agent Customer
12 WORLD FORECAST REVIEW FOR PROSTATE CANCER-TARGETED PET IMAGING AGENT BY GEOGRAPHIC REGION
12.1 Global Prostate Cancer-targeted PET Imaging Agent Market Size Forecast by Region
12.1.1 Global Prostate Cancer-targeted PET Imaging Agent Forecast by Region (2027-2032)
12.1.2 Global Prostate Cancer-targeted PET Imaging Agent Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Prostate Cancer-targeted PET Imaging Agent Forecast by Type (2027-2032)
12.7 Global Prostate Cancer-targeted PET Imaging Agent Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Lantheus
13.1.1 Lantheus Company Information
13.1.2 Lantheus Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.1.3 Lantheus Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Lantheus Main Business Overview
13.1.5 Lantheus Latest Developments
13.2 Telix Pharmaceuticals
13.2.1 Telix Pharmaceuticals Company Information
13.2.2 Telix Pharmaceuticals Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.2.3 Telix Pharmaceuticals Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 Telix Pharmaceuticals Main Business Overview
13.2.5 Telix Pharmaceuticals Latest Developments
13.3 Novartis
13.3.1 Novartis Company Information
13.3.2 Novartis Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.3.3 Novartis Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Novartis Main Business Overview
13.3.5 Novartis Latest Developments
13.4 Blue Earth Diagnostics?Bracco?
13.4.1 Blue Earth Diagnostics?Bracco? Company Information
13.4.2 Blue Earth Diagnostics?Bracco? Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.4.3 Blue Earth Diagnostics?Bracco? Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Blue Earth Diagnostics?Bracco? Main Business Overview
13.4.5 Blue Earth Diagnostics?Bracco? Latest Developments
13.5 Sinotau
13.5.1 Sinotau Company Information
13.5.2 Sinotau Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.5.3 Sinotau Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sinotau Main Business Overview
13.5.5 Sinotau Latest Developments
13.6 DC PHARMA
13.6.1 DC PHARMA Company Information
13.6.2 DC PHARMA Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.6.3 DC PHARMA Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 DC PHARMA Main Business Overview
13.6.5 DC PHARMA Latest Developments
13.7 Clarity Pharmaceuticals
13.7.1 Clarity Pharmaceuticals Company Information
13.7.2 Clarity Pharmaceuticals Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.7.3 Clarity Pharmaceuticals Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Clarity Pharmaceuticals Main Business Overview
13.7.5 Clarity Pharmaceuticals Latest Developments
13.8 Hengrui Pharma
13.8.1 Hengrui Pharma Company Information
13.8.2 Hengrui Pharma Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.8.3 Hengrui Pharma Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Hengrui Pharma Main Business Overview
13.8.5 Hengrui Pharma Latest Developments
13.9 CRAND PHARMACEUTICAL
13.9.1 CRAND PHARMACEUTICAL Company Information
13.9.2 CRAND PHARMACEUTICAL Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.9.3 CRAND PHARMACEUTICAL Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 CRAND PHARMACEUTICAL Main Business Overview
13.9.5 CRAND PHARMACEUTICAL Latest Developments
13.10 Norroy Bioscience
13.10.1 Norroy Bioscience Company Information
13.10.2 Norroy Bioscience Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.10.3 Norroy Bioscience Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Norroy Bioscience Main Business Overview
13.10.5 Norroy Bioscience Latest Developments
13.11 HUAYI RADIOPHARMACEUTICALS
13.11.1 HUAYI RADIOPHARMACEUTICALS Company Information
13.11.2 HUAYI RADIOPHARMACEUTICALS Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.11.3 HUAYI RADIOPHARMACEUTICALS Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 HUAYI RADIOPHARMACEUTICALS Main Business Overview
13.11.5 HUAYI RADIOPHARMACEUTICALS Latest Developments
13.12 Yunhe Pharma
13.12.1 Yunhe Pharma Company Information
13.12.2 Yunhe Pharma Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.12.3 Yunhe Pharma Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 Yunhe Pharma Main Business Overview
13.12.5 Yunhe Pharma Latest Developments
13.13 C Ray Therapeutics
13.13.1 C Ray Therapeutics Company Information
13.13.2 C Ray Therapeutics Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.13.3 C Ray Therapeutics Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 C Ray Therapeutics Main Business Overview
13.13.5 C Ray Therapeutics Latest Developments
13.14 Curium Holding France S.A.S.
13.14.1 Curium Holding France S.A.S. Company Information
13.14.2 Curium Holding France S.A.S. Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.14.3 Curium Holding France S.A.S. Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Curium Holding France S.A.S. Main Business Overview
13.14.5 Curium Holding France S.A.S. Latest Developments
13.15 ABX advanced biochemical compounds GmbH
13.15.1 ABX advanced biochemical compounds GmbH Company Information
13.15.2 ABX advanced biochemical compounds GmbH Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.15.3 ABX advanced biochemical compounds GmbH Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 ABX advanced biochemical compounds GmbH Main Business Overview
13.15.5 ABX advanced biochemical compounds GmbH Latest Developments
13.16 Isotopia Molecular Imaging Ltd.
13.16.1 Isotopia Molecular Imaging Ltd. Company Information
13.16.2 Isotopia Molecular Imaging Ltd. Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
13.16.3 Isotopia Molecular Imaging Ltd. Prostate Cancer-targeted PET Imaging Agent Sales, Revenue, Price and Gross Margin (2021-2026)
13.16.4 Isotopia Molecular Imaging Ltd. Main Business Overview
13.16.5 Isotopia Molecular Imaging Ltd. Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Prostate Cancer-targeted PET Imaging Agent Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Prostate Cancer-targeted PET Imaging Agent Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 68Ga
Table 4. Major Players of 18F
Table 5. Global Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026) & (K Units)
Table 6. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Type (2021-2026)
Table 7. Global Prostate Cancer-targeted PET Imaging Agent Revenue by Type (2021-2026) & ($ million)
Table 8. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Type (2021-2026)
Table 9. Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of First Generation
Table 11. Major Players of Second Generation
Table 12. Global Prostate Cancer-targeted PET Imaging Agent Sales by Core Carrier Materials (2021-2026) & (K Units)
Table 13. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Core Carrier Materials (2021-2026)
Table 14. Global Prostate Cancer-targeted PET Imaging Agent Revenue by Core Carrier Materials (2021-2026) & ($ million)
Table 15. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Core Carrier Materials (2021-2026)
Table 16. Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Core Carrier Materials (2021-2026) & (US$/Unit)
Table 17. Major Players of Active Targeting
Table 18. Major Players of Passive Targeting
Table 19. Global Prostate Cancer-targeted PET Imaging Agent Sales by Mechanism of Action (2021-2026) & (K Units)
Table 20. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Mechanism of Action (2021-2026)
Table 21. Global Prostate Cancer-targeted PET Imaging Agent Revenue by Mechanism of Action (2021-2026) & ($ million)
Table 22. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Mechanism of Action (2021-2026)
Table 23. Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Mechanism of Action (2021-2026) & (US$/Unit)
Table 24. Global Prostate Cancer-targeted PET Imaging Agent Sale by Application (2021-2026) & (K Units)
Table 25. Global Prostate Cancer-targeted PET Imaging Agent Sale Market Share by Application (2021-2026)
Table 26. Global Prostate Cancer-targeted PET Imaging Agent Revenue by Application (2021-2026) & ($ million)
Table 27. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Application (2021-2026)
Table 28. Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Application (2021-2026) & (US$/Unit)
Table 29. Global Prostate Cancer-targeted PET Imaging Agent Sales by Company (2021-2026) & (K Units)
Table 30. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Company (2021-2026)
Table 31. Global Prostate Cancer-targeted PET Imaging Agent Revenue by Company (2021-2026) & ($ millions)
Table 32. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Company (2021-2026)
Table 33. Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Company (2021-2026) & (US$/Unit)
Table 34. Key Manufacturers Prostate Cancer-targeted PET Imaging Agent Producing Area Distribution and Sales Area
Table 35. Players Prostate Cancer-targeted PET Imaging Agent Products Offered
Table 36. Prostate Cancer-targeted PET Imaging Agent Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 37. New Products and Potential Entrants
Table 38. Market M&A Activity & Strategy
Table 39. Global Prostate Cancer-targeted PET Imaging Agent Sales by Geographic Region (2021-2026) & (K Units)
Table 40. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share Geographic Region (2021-2026)
Table 41. Global Prostate Cancer-targeted PET Imaging Agent Revenue by Geographic Region (2021-2026) & ($ millions)
Table 42. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Geographic Region (2021-2026)
Table 43. Global Prostate Cancer-targeted PET Imaging Agent Sales by Country/Region (2021-2026) & (K Units)
Table 44. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Country/Region (2021-2026)
Table 45. Global Prostate Cancer-targeted PET Imaging Agent Revenue by Country/Region (2021-2026) & ($ millions)
Table 46. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Country/Region (2021-2026)
Table 47. Americas Prostate Cancer-targeted PET Imaging Agent Sales by Country (2021-2026) & (K Units)
Table 48. Americas Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Country (2021-2026)
Table 49. Americas Prostate Cancer-targeted PET Imaging Agent Revenue by Country (2021-2026) & ($ millions)
Table 50. Americas Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026) & (K Units)
Table 51. Americas Prostate Cancer-targeted PET Imaging Agent Sales by Application (2021-2026) & (K Units)
Table 52. APAC Prostate Cancer-targeted PET Imaging Agent Sales by Region (2021-2026) & (K Units)
Table 53. APAC Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Region (2021-2026)
Table 54. APAC Prostate Cancer-targeted PET Imaging Agent Revenue by Region (2021-2026) & ($ millions)
Table 55. APAC Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026) & (K Units)
Table 56. APAC Prostate Cancer-targeted PET Imaging Agent Sales by Application (2021-2026) & (K Units)
Table 57. Europe Prostate Cancer-targeted PET Imaging Agent Sales by Country (2021-2026) & (K Units)
Table 58. Europe Prostate Cancer-targeted PET Imaging Agent Revenue by Country (2021-2026) & ($ millions)
Table 59. Europe Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026) & (K Units)
Table 60. Europe Prostate Cancer-targeted PET Imaging Agent Sales by Application (2021-2026) & (K Units)
Table 61. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales by Country (2021-2026) & (K Units)
Table 62. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Country (2021-2026)
Table 63. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026) & (K Units)
Table 64. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales by Application (2021-2026) & (K Units)
Table 65. Key Market Drivers & Growth Opportunities of Prostate Cancer-targeted PET Imaging Agent
Table 66. Key Market Challenges & Risks of Prostate Cancer-targeted PET Imaging Agent
Table 67. Key Industry Trends of Prostate Cancer-targeted PET Imaging Agent
Table 68. Prostate Cancer-targeted PET Imaging Agent Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Prostate Cancer-targeted PET Imaging Agent Distributors List
Table 71. Prostate Cancer-targeted PET Imaging Agent Customer List
Table 72. Global Prostate Cancer-targeted PET Imaging Agent Sales Forecast by Region (2027-2032) & (K Units)
Table 73. Global Prostate Cancer-targeted PET Imaging Agent Revenue Forecast by Region (2027-2032) & ($ millions)
Table 74. Americas Prostate Cancer-targeted PET Imaging Agent Sales Forecast by Country (2027-2032) & (K Units)
Table 75. Americas Prostate Cancer-targeted PET Imaging Agent Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 76. APAC Prostate Cancer-targeted PET Imaging Agent Sales Forecast by Region (2027-2032) & (K Units)
Table 77. APAC Prostate Cancer-targeted PET Imaging Agent Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 78. Europe Prostate Cancer-targeted PET Imaging Agent Sales Forecast by Country (2027-2032) & (K Units)
Table 79. Europe Prostate Cancer-targeted PET Imaging Agent Revenue Forecast by Country (2027-2032) & ($ millions)
Table 80. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales Forecast by Country (2027-2032) & (K Units)
Table 81. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Global Prostate Cancer-targeted PET Imaging Agent Sales Forecast by Type (2027-2032) & (K Units)
Table 83. Global Prostate Cancer-targeted PET Imaging Agent Revenue Forecast by Type (2027-2032) & ($ millions)
Table 84. Global Prostate Cancer-targeted PET Imaging Agent Sales Forecast by Application (2027-2032) & (K Units)
Table 85. Global Prostate Cancer-targeted PET Imaging Agent Revenue Forecast by Application (2027-2032) & ($ millions)
Table 86. Lantheus Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 87. Lantheus Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 88. Lantheus Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. Lantheus Main Business
Table 90. Lantheus Latest Developments
Table 91. Telix Pharmaceuticals Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 92. Telix Pharmaceuticals Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 93. Telix Pharmaceuticals Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. Telix Pharmaceuticals Main Business
Table 95. Telix Pharmaceuticals Latest Developments
Table 96. Novartis Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 97. Novartis Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 98. Novartis Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 99. Novartis Main Business
Table 100. Novartis Latest Developments
Table 101. Blue Earth Diagnostics?Bracco? Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 102. Blue Earth Diagnostics?Bracco? Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 103. Blue Earth Diagnostics?Bracco? Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 104. Blue Earth Diagnostics?Bracco? Main Business
Table 105. Blue Earth Diagnostics?Bracco? Latest Developments
Table 106. Sinotau Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 107. Sinotau Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 108. Sinotau Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 109. Sinotau Main Business
Table 110. Sinotau Latest Developments
Table 111. DC PHARMA Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 112. DC PHARMA Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 113. DC PHARMA Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 114. DC PHARMA Main Business
Table 115. DC PHARMA Latest Developments
Table 116. Clarity Pharmaceuticals Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 117. Clarity Pharmaceuticals Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 118. Clarity Pharmaceuticals Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 119. Clarity Pharmaceuticals Main Business
Table 120. Clarity Pharmaceuticals Latest Developments
Table 121. Hengrui Pharma Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 122. Hengrui Pharma Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 123. Hengrui Pharma Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 124. Hengrui Pharma Main Business
Table 125. Hengrui Pharma Latest Developments
Table 126. CRAND PHARMACEUTICAL Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 127. CRAND PHARMACEUTICAL Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 128. CRAND PHARMACEUTICAL Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 129. CRAND PHARMACEUTICAL Main Business
Table 130. CRAND PHARMACEUTICAL Latest Developments
Table 131. Norroy Bioscience Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 132. Norroy Bioscience Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 133. Norroy Bioscience Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 134. Norroy Bioscience Main Business
Table 135. Norroy Bioscience Latest Developments
Table 136. HUAYI RADIOPHARMACEUTICALS Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 137. HUAYI RADIOPHARMACEUTICALS Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 138. HUAYI RADIOPHARMACEUTICALS Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 139. HUAYI RADIOPHARMACEUTICALS Main Business
Table 140. HUAYI RADIOPHARMACEUTICALS Latest Developments
Table 141. Yunhe Pharma Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 142. Yunhe Pharma Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 143. Yunhe Pharma Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 144. Yunhe Pharma Main Business
Table 145. Yunhe Pharma Latest Developments
Table 146. C Ray Therapeutics Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 147. C Ray Therapeutics Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 148. C Ray Therapeutics Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 149. C Ray Therapeutics Main Business
Table 150. C Ray Therapeutics Latest Developments
Table 151. Curium Holding France S.A.S. Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 152. Curium Holding France S.A.S. Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 153. Curium Holding France S.A.S. Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 154. Curium Holding France S.A.S. Main Business
Table 155. Curium Holding France S.A.S. Latest Developments
Table 156. ABX advanced biochemical compounds GmbH Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 157. ABX advanced biochemical compounds GmbH Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 158. ABX advanced biochemical compounds GmbH Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 159. ABX advanced biochemical compounds GmbH Main Business
Table 160. ABX advanced biochemical compounds GmbH Latest Developments
Table 161. Isotopia Molecular Imaging Ltd. Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 162. Isotopia Molecular Imaging Ltd. Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 163. Isotopia Molecular Imaging Ltd. Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 164. Isotopia Molecular Imaging Ltd. Main Business
Table 165. Isotopia Molecular Imaging Ltd. Latest Developments
Table 1. Prostate Cancer-targeted PET Imaging Agent Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Prostate Cancer-targeted PET Imaging Agent Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of 68Ga
Table 4. Major Players of 18F
Table 5. Global Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026) & (K Units)
Table 6. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Type (2021-2026)
Table 7. Global Prostate Cancer-targeted PET Imaging Agent Revenue by Type (2021-2026) & ($ million)
Table 8. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Type (2021-2026)
Table 9. Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Type (2021-2026) & (US$/Unit)
Table 10. Major Players of First Generation
Table 11. Major Players of Second Generation
Table 12. Global Prostate Cancer-targeted PET Imaging Agent Sales by Core Carrier Materials (2021-2026) & (K Units)
Table 13. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Core Carrier Materials (2021-2026)
Table 14. Global Prostate Cancer-targeted PET Imaging Agent Revenue by Core Carrier Materials (2021-2026) & ($ million)
Table 15. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Core Carrier Materials (2021-2026)
Table 16. Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Core Carrier Materials (2021-2026) & (US$/Unit)
Table 17. Major Players of Active Targeting
Table 18. Major Players of Passive Targeting
Table 19. Global Prostate Cancer-targeted PET Imaging Agent Sales by Mechanism of Action (2021-2026) & (K Units)
Table 20. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Mechanism of Action (2021-2026)
Table 21. Global Prostate Cancer-targeted PET Imaging Agent Revenue by Mechanism of Action (2021-2026) & ($ million)
Table 22. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Mechanism of Action (2021-2026)
Table 23. Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Mechanism of Action (2021-2026) & (US$/Unit)
Table 24. Global Prostate Cancer-targeted PET Imaging Agent Sale by Application (2021-2026) & (K Units)
Table 25. Global Prostate Cancer-targeted PET Imaging Agent Sale Market Share by Application (2021-2026)
Table 26. Global Prostate Cancer-targeted PET Imaging Agent Revenue by Application (2021-2026) & ($ million)
Table 27. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Application (2021-2026)
Table 28. Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Application (2021-2026) & (US$/Unit)
Table 29. Global Prostate Cancer-targeted PET Imaging Agent Sales by Company (2021-2026) & (K Units)
Table 30. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Company (2021-2026)
Table 31. Global Prostate Cancer-targeted PET Imaging Agent Revenue by Company (2021-2026) & ($ millions)
Table 32. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Company (2021-2026)
Table 33. Global Prostate Cancer-targeted PET Imaging Agent Sale Price by Company (2021-2026) & (US$/Unit)
Table 34. Key Manufacturers Prostate Cancer-targeted PET Imaging Agent Producing Area Distribution and Sales Area
Table 35. Players Prostate Cancer-targeted PET Imaging Agent Products Offered
Table 36. Prostate Cancer-targeted PET Imaging Agent Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 37. New Products and Potential Entrants
Table 38. Market M&A Activity & Strategy
Table 39. Global Prostate Cancer-targeted PET Imaging Agent Sales by Geographic Region (2021-2026) & (K Units)
Table 40. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share Geographic Region (2021-2026)
Table 41. Global Prostate Cancer-targeted PET Imaging Agent Revenue by Geographic Region (2021-2026) & ($ millions)
Table 42. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Geographic Region (2021-2026)
Table 43. Global Prostate Cancer-targeted PET Imaging Agent Sales by Country/Region (2021-2026) & (K Units)
Table 44. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Country/Region (2021-2026)
Table 45. Global Prostate Cancer-targeted PET Imaging Agent Revenue by Country/Region (2021-2026) & ($ millions)
Table 46. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Country/Region (2021-2026)
Table 47. Americas Prostate Cancer-targeted PET Imaging Agent Sales by Country (2021-2026) & (K Units)
Table 48. Americas Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Country (2021-2026)
Table 49. Americas Prostate Cancer-targeted PET Imaging Agent Revenue by Country (2021-2026) & ($ millions)
Table 50. Americas Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026) & (K Units)
Table 51. Americas Prostate Cancer-targeted PET Imaging Agent Sales by Application (2021-2026) & (K Units)
Table 52. APAC Prostate Cancer-targeted PET Imaging Agent Sales by Region (2021-2026) & (K Units)
Table 53. APAC Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Region (2021-2026)
Table 54. APAC Prostate Cancer-targeted PET Imaging Agent Revenue by Region (2021-2026) & ($ millions)
Table 55. APAC Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026) & (K Units)
Table 56. APAC Prostate Cancer-targeted PET Imaging Agent Sales by Application (2021-2026) & (K Units)
Table 57. Europe Prostate Cancer-targeted PET Imaging Agent Sales by Country (2021-2026) & (K Units)
Table 58. Europe Prostate Cancer-targeted PET Imaging Agent Revenue by Country (2021-2026) & ($ millions)
Table 59. Europe Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026) & (K Units)
Table 60. Europe Prostate Cancer-targeted PET Imaging Agent Sales by Application (2021-2026) & (K Units)
Table 61. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales by Country (2021-2026) & (K Units)
Table 62. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Country (2021-2026)
Table 63. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales by Type (2021-2026) & (K Units)
Table 64. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales by Application (2021-2026) & (K Units)
Table 65. Key Market Drivers & Growth Opportunities of Prostate Cancer-targeted PET Imaging Agent
Table 66. Key Market Challenges & Risks of Prostate Cancer-targeted PET Imaging Agent
Table 67. Key Industry Trends of Prostate Cancer-targeted PET Imaging Agent
Table 68. Prostate Cancer-targeted PET Imaging Agent Raw Material
Table 69. Key Suppliers of Raw Materials
Table 70. Prostate Cancer-targeted PET Imaging Agent Distributors List
Table 71. Prostate Cancer-targeted PET Imaging Agent Customer List
Table 72. Global Prostate Cancer-targeted PET Imaging Agent Sales Forecast by Region (2027-2032) & (K Units)
Table 73. Global Prostate Cancer-targeted PET Imaging Agent Revenue Forecast by Region (2027-2032) & ($ millions)
Table 74. Americas Prostate Cancer-targeted PET Imaging Agent Sales Forecast by Country (2027-2032) & (K Units)
Table 75. Americas Prostate Cancer-targeted PET Imaging Agent Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 76. APAC Prostate Cancer-targeted PET Imaging Agent Sales Forecast by Region (2027-2032) & (K Units)
Table 77. APAC Prostate Cancer-targeted PET Imaging Agent Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 78. Europe Prostate Cancer-targeted PET Imaging Agent Sales Forecast by Country (2027-2032) & (K Units)
Table 79. Europe Prostate Cancer-targeted PET Imaging Agent Revenue Forecast by Country (2027-2032) & ($ millions)
Table 80. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales Forecast by Country (2027-2032) & (K Units)
Table 81. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Global Prostate Cancer-targeted PET Imaging Agent Sales Forecast by Type (2027-2032) & (K Units)
Table 83. Global Prostate Cancer-targeted PET Imaging Agent Revenue Forecast by Type (2027-2032) & ($ millions)
Table 84. Global Prostate Cancer-targeted PET Imaging Agent Sales Forecast by Application (2027-2032) & (K Units)
Table 85. Global Prostate Cancer-targeted PET Imaging Agent Revenue Forecast by Application (2027-2032) & ($ millions)
Table 86. Lantheus Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 87. Lantheus Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 88. Lantheus Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. Lantheus Main Business
Table 90. Lantheus Latest Developments
Table 91. Telix Pharmaceuticals Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 92. Telix Pharmaceuticals Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 93. Telix Pharmaceuticals Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 94. Telix Pharmaceuticals Main Business
Table 95. Telix Pharmaceuticals Latest Developments
Table 96. Novartis Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 97. Novartis Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 98. Novartis Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 99. Novartis Main Business
Table 100. Novartis Latest Developments
Table 101. Blue Earth Diagnostics?Bracco? Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 102. Blue Earth Diagnostics?Bracco? Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 103. Blue Earth Diagnostics?Bracco? Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 104. Blue Earth Diagnostics?Bracco? Main Business
Table 105. Blue Earth Diagnostics?Bracco? Latest Developments
Table 106. Sinotau Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 107. Sinotau Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 108. Sinotau Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 109. Sinotau Main Business
Table 110. Sinotau Latest Developments
Table 111. DC PHARMA Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 112. DC PHARMA Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 113. DC PHARMA Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 114. DC PHARMA Main Business
Table 115. DC PHARMA Latest Developments
Table 116. Clarity Pharmaceuticals Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 117. Clarity Pharmaceuticals Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 118. Clarity Pharmaceuticals Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 119. Clarity Pharmaceuticals Main Business
Table 120. Clarity Pharmaceuticals Latest Developments
Table 121. Hengrui Pharma Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 122. Hengrui Pharma Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 123. Hengrui Pharma Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 124. Hengrui Pharma Main Business
Table 125. Hengrui Pharma Latest Developments
Table 126. CRAND PHARMACEUTICAL Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 127. CRAND PHARMACEUTICAL Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 128. CRAND PHARMACEUTICAL Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 129. CRAND PHARMACEUTICAL Main Business
Table 130. CRAND PHARMACEUTICAL Latest Developments
Table 131. Norroy Bioscience Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 132. Norroy Bioscience Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 133. Norroy Bioscience Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 134. Norroy Bioscience Main Business
Table 135. Norroy Bioscience Latest Developments
Table 136. HUAYI RADIOPHARMACEUTICALS Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 137. HUAYI RADIOPHARMACEUTICALS Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 138. HUAYI RADIOPHARMACEUTICALS Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 139. HUAYI RADIOPHARMACEUTICALS Main Business
Table 140. HUAYI RADIOPHARMACEUTICALS Latest Developments
Table 141. Yunhe Pharma Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 142. Yunhe Pharma Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 143. Yunhe Pharma Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 144. Yunhe Pharma Main Business
Table 145. Yunhe Pharma Latest Developments
Table 146. C Ray Therapeutics Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 147. C Ray Therapeutics Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 148. C Ray Therapeutics Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 149. C Ray Therapeutics Main Business
Table 150. C Ray Therapeutics Latest Developments
Table 151. Curium Holding France S.A.S. Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 152. Curium Holding France S.A.S. Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 153. Curium Holding France S.A.S. Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 154. Curium Holding France S.A.S. Main Business
Table 155. Curium Holding France S.A.S. Latest Developments
Table 156. ABX advanced biochemical compounds GmbH Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 157. ABX advanced biochemical compounds GmbH Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 158. ABX advanced biochemical compounds GmbH Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 159. ABX advanced biochemical compounds GmbH Main Business
Table 160. ABX advanced biochemical compounds GmbH Latest Developments
Table 161. Isotopia Molecular Imaging Ltd. Basic Information, Prostate Cancer-targeted PET Imaging Agent Manufacturing Base, Sales Area and Its Competitors
Table 162. Isotopia Molecular Imaging Ltd. Prostate Cancer-targeted PET Imaging Agent Product Portfolios and Specifications
Table 163. Isotopia Molecular Imaging Ltd. Prostate Cancer-targeted PET Imaging Agent Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 164. Isotopia Molecular Imaging Ltd. Main Business
Table 165. Isotopia Molecular Imaging Ltd. Latest Developments
LIST OF FIGURES
Figure 1. Picture of Prostate Cancer-targeted PET Imaging Agent
Figure 2. Prostate Cancer-targeted PET Imaging Agent Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Prostate Cancer-targeted PET Imaging Agent Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Prostate Cancer-targeted PET Imaging Agent Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Prostate Cancer-targeted PET Imaging Agent Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Country/Region (2025)
Figure 10. Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 68Ga
Figure 12. Product Picture of 18F
Figure 13. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Type in 2026
Figure 14. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of First Generation
Figure 16. Product Picture of Second Generation
Figure 17. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Core Carrier Materials in 2026
Figure 18. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Core Carrier Materials (2021-2026)
Figure 19. Product Picture of Active Targeting
Figure 20. Product Picture of Passive Targeting
Figure 21. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Mechanism of Action in 2026
Figure 22. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Mechanism of Action (2021-2026)
Figure 23. Prostate Cancer-targeted PET Imaging Agent Consumed in Nuclear Medicine and Molecular Imaging
Figure 24. Global Prostate Cancer-targeted PET Imaging Agent Market: Nuclear Medicine and Molecular Imaging (2021-2026) & (K Units)
Figure 25. Prostate Cancer-targeted PET Imaging Agent Consumed in Precision Oncology Diagnostics
Figure 26. Global Prostate Cancer-targeted PET Imaging Agent Market: Precision Oncology Diagnostics (2021-2026) & (K Units)
Figure 27. Prostate Cancer-targeted PET Imaging Agent Consumed in Radiopharmaceuticals and Radiopharmaceuticals
Figure 28. Global Prostate Cancer-targeted PET Imaging Agent Market: Radiopharmaceuticals and Radiopharmaceuticals (2021-2026) & (K Units)
Figure 29. Global Prostate Cancer-targeted PET Imaging Agent Sale Market Share by Application (2025)
Figure 30. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Application in 2025
Figure 31. Prostate Cancer-targeted PET Imaging Agent Sales by Company in 2025 (K Units)
Figure 32. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Company in 2025
Figure 33. Prostate Cancer-targeted PET Imaging Agent Revenue by Company in 2025 ($ millions)
Figure 34. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Company in 2025
Figure 35. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Geographic Region (2021-2026)
Figure 36. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Geographic Region in 2025
Figure 37. Americas Prostate Cancer-targeted PET Imaging Agent Sales 2021-2026 (K Units)
Figure 38. Americas Prostate Cancer-targeted PET Imaging Agent Revenue 2021-2026 ($ millions)
Figure 39. APAC Prostate Cancer-targeted PET Imaging Agent Sales 2021-2026 (K Units)
Figure 40. APAC Prostate Cancer-targeted PET Imaging Agent Revenue 2021-2026 ($ millions)
Figure 41. Europe Prostate Cancer-targeted PET Imaging Agent Sales 2021-2026 (K Units)
Figure 42. Europe Prostate Cancer-targeted PET Imaging Agent Revenue 2021-2026 ($ millions)
Figure 43. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales 2021-2026 (K Units)
Figure 44. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Revenue 2021-2026 ($ millions)
Figure 45. Americas Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Country in 2025
Figure 46. Americas Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Country (2021-2026)
Figure 47. Americas Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Type (2021-2026)
Figure 48. Americas Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Application (2021-2026)
Figure 49. United States Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 50. Canada Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 51. Mexico Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 52. Brazil Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 53. APAC Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Region in 2025
Figure 54. APAC Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Region (2021-2026)
Figure 55. APAC Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Type (2021-2026)
Figure 56. APAC Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Application (2021-2026)
Figure 57. China Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 58. Japan Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 59. South Korea Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 60. Southeast Asia Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 61. India Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 62. Australia Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 63. China Taiwan Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 64. Europe Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Country in 2025
Figure 65. Europe Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Country (2021-2026)
Figure 66. Europe Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Type (2021-2026)
Figure 67. Europe Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Application (2021-2026)
Figure 68. Germany Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 69. France Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 70. UK Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 71. Italy Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 72. Russia Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 73. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Country (2021-2026)
Figure 74. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Type (2021-2026)
Figure 75. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Application (2021-2026)
Figure 76. Egypt Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 77. South Africa Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 78. Israel Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 79. Turkey Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 80. GCC Countries Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 81. Manufacturing Cost Structure Analysis of Prostate Cancer-targeted PET Imaging Agent in 2026
Figure 82. Manufacturing Process Analysis of Prostate Cancer-targeted PET Imaging Agent
Figure 83. Industry Chain Structure of Prostate Cancer-targeted PET Imaging Agent
Figure 84. Channels of Distribution
Figure 85. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Forecast by Region (2027-2032)
Figure 86. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share Forecast by Region (2027-2032)
Figure 87. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share Forecast by Type (2027-2032)
Figure 88. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share Forecast by Type (2027-2032)
Figure 89. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share Forecast by Application (2027-2032)
Figure 90. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Prostate Cancer-targeted PET Imaging Agent
Figure 2. Prostate Cancer-targeted PET Imaging Agent Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Prostate Cancer-targeted PET Imaging Agent Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Prostate Cancer-targeted PET Imaging Agent Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Prostate Cancer-targeted PET Imaging Agent Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Country/Region (2025)
Figure 10. Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of 68Ga
Figure 12. Product Picture of 18F
Figure 13. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Type in 2026
Figure 14. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Type (2021-2026)
Figure 15. Product Picture of First Generation
Figure 16. Product Picture of Second Generation
Figure 17. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Core Carrier Materials in 2026
Figure 18. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Core Carrier Materials (2021-2026)
Figure 19. Product Picture of Active Targeting
Figure 20. Product Picture of Passive Targeting
Figure 21. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Mechanism of Action in 2026
Figure 22. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Mechanism of Action (2021-2026)
Figure 23. Prostate Cancer-targeted PET Imaging Agent Consumed in Nuclear Medicine and Molecular Imaging
Figure 24. Global Prostate Cancer-targeted PET Imaging Agent Market: Nuclear Medicine and Molecular Imaging (2021-2026) & (K Units)
Figure 25. Prostate Cancer-targeted PET Imaging Agent Consumed in Precision Oncology Diagnostics
Figure 26. Global Prostate Cancer-targeted PET Imaging Agent Market: Precision Oncology Diagnostics (2021-2026) & (K Units)
Figure 27. Prostate Cancer-targeted PET Imaging Agent Consumed in Radiopharmaceuticals and Radiopharmaceuticals
Figure 28. Global Prostate Cancer-targeted PET Imaging Agent Market: Radiopharmaceuticals and Radiopharmaceuticals (2021-2026) & (K Units)
Figure 29. Global Prostate Cancer-targeted PET Imaging Agent Sale Market Share by Application (2025)
Figure 30. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Application in 2025
Figure 31. Prostate Cancer-targeted PET Imaging Agent Sales by Company in 2025 (K Units)
Figure 32. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Company in 2025
Figure 33. Prostate Cancer-targeted PET Imaging Agent Revenue by Company in 2025 ($ millions)
Figure 34. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Company in 2025
Figure 35. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Geographic Region (2021-2026)
Figure 36. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Geographic Region in 2025
Figure 37. Americas Prostate Cancer-targeted PET Imaging Agent Sales 2021-2026 (K Units)
Figure 38. Americas Prostate Cancer-targeted PET Imaging Agent Revenue 2021-2026 ($ millions)
Figure 39. APAC Prostate Cancer-targeted PET Imaging Agent Sales 2021-2026 (K Units)
Figure 40. APAC Prostate Cancer-targeted PET Imaging Agent Revenue 2021-2026 ($ millions)
Figure 41. Europe Prostate Cancer-targeted PET Imaging Agent Sales 2021-2026 (K Units)
Figure 42. Europe Prostate Cancer-targeted PET Imaging Agent Revenue 2021-2026 ($ millions)
Figure 43. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales 2021-2026 (K Units)
Figure 44. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Revenue 2021-2026 ($ millions)
Figure 45. Americas Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Country in 2025
Figure 46. Americas Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Country (2021-2026)
Figure 47. Americas Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Type (2021-2026)
Figure 48. Americas Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Application (2021-2026)
Figure 49. United States Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 50. Canada Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 51. Mexico Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 52. Brazil Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 53. APAC Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Region in 2025
Figure 54. APAC Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Region (2021-2026)
Figure 55. APAC Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Type (2021-2026)
Figure 56. APAC Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Application (2021-2026)
Figure 57. China Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 58. Japan Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 59. South Korea Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 60. Southeast Asia Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 61. India Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 62. Australia Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 63. China Taiwan Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 64. Europe Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Country in 2025
Figure 65. Europe Prostate Cancer-targeted PET Imaging Agent Revenue Market Share by Country (2021-2026)
Figure 66. Europe Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Type (2021-2026)
Figure 67. Europe Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Application (2021-2026)
Figure 68. Germany Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 69. France Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 70. UK Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 71. Italy Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 72. Russia Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 73. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Country (2021-2026)
Figure 74. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Type (2021-2026)
Figure 75. Middle East & Africa Prostate Cancer-targeted PET Imaging Agent Sales Market Share by Application (2021-2026)
Figure 76. Egypt Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 77. South Africa Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 78. Israel Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 79. Turkey Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 80. GCC Countries Prostate Cancer-targeted PET Imaging Agent Revenue Growth 2021-2026 ($ millions)
Figure 81. Manufacturing Cost Structure Analysis of Prostate Cancer-targeted PET Imaging Agent in 2026
Figure 82. Manufacturing Process Analysis of Prostate Cancer-targeted PET Imaging Agent
Figure 83. Industry Chain Structure of Prostate Cancer-targeted PET Imaging Agent
Figure 84. Channels of Distribution
Figure 85. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Forecast by Region (2027-2032)
Figure 86. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share Forecast by Region (2027-2032)
Figure 87. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share Forecast by Type (2027-2032)
Figure 88. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share Forecast by Type (2027-2032)
Figure 89. Global Prostate Cancer-targeted PET Imaging Agent Sales Market Share Forecast by Application (2027-2032)
Figure 90. Global Prostate Cancer-targeted PET Imaging Agent Revenue Market Share Forecast by Application (2027-2032)
